Posts filtered by tags: Biotech[x]


 

IoT and data science will boost foodtech in the post-pandemic era

Sunny Dhillon Contributor Share on Twitter Sunny Dhillon is an early-stage investor at Signia Ventures in San Francisco where he invests in retail tech, e-commerce infrastructure and logistics, alongside consumer and enterprise software startups. More posts by this contributor From farm to phone: A paradigm shift in grocery An optimistic view of deepfakes Even as e-grocery usage has skyrocketed ...
Tags: Food, Startups, TC, Ecommerce, Column, Internet Of Things, Science, San Francisco, Tech, Walmart, Supermarkets, Data Science, Venture Capital, Fda, Food Waste, Iot


AbbVie Exits Editas Alliance, Pruning Another Genetic Medicines Pact

AbbVie has terminated a research partnership with Editas Medicines, returning to the biotech rights to an experimental gene-editing treatment. It’s the second genetic medicines alliance the pharmaceutical company exited this week.The Editas therapy, EDIT-101, is in Phase 1 testing as a treatment for a rare, inherited form of blindness called Leber congenital amaurosis type 10 (LCA10). It uses the CRISPR technology to edit the mutated gene that causes the disease. The therapy does its editing in...
Tags: Deals, Boston, Trends, Alzheimer's Disease, Parkinson's Disease, Allergan, Abbvie, Biotech, Crispr, Life Sciences, Editas Medicine, Clinical Trials, Cynthia Collins, Gene Editing, Leber, Cambridge MA


Bio Roundup: A Telehealth Combo, FDA’s BCMA OK, Biogen’s Bet & More

The novel coronavirus has driven the pharmaceutical industry to upend its research priorities. Big Pharma companies are focusing on vaccine development and a slew of biotechs are testing compounds, previously intended for a wide range of indications, as potential COVID-19 treatments.This week saw another major development brought on by industry efforts to adjust to the new realities engendered by the pandemic, with the signing of an $18.5 billion merger in the digital health sector. How the tie...
Tags: Deals, Startups, Trends, Merck, Venture Capital, Fda, National, GlaxoSmithKline, Novartis, Abbvie, Biotech, Khosla Ventures, Life Sciences, Big Pharma, Sanofi, Valeant Pharmaceuticals


As Patients Pivot to Telehealth, Teladoc & Livongo Plan $18.5B Tie-Up

Telemedicine giant Teladoc Health is buying health technology company Livongo Health in an $18.5 billion cash and stock deal that comes as the COVID-19 pandemic drives patients to seek ways to manage their health from home.Teladoc (NYSE: TDOC) provides “virtual healthcare services” that give patients the ability to visit with a doctor remotely. Most of its clients are large companies and health plans that offer Teladoc’s services to their employees or beneficiaries, though it does have individu...
Tags: Deals, New York, Trends, Software, Diabetes, Hypertension, Biotech, Telemedicine, Life Sciences, Glen Tullman, Livongo Health, TDOC, National blog main, New York blog main, New York top stories, National top stories


GentiBio Joins Cell Therapy Chase With $20M and New Treg Technology

One of the challenges facing cell therapy developers is collecting enough cells to produce a viable treatment. It’s a particularly pronounced problem for therapies employing regulatory T cells (Tregs), a type of immune cell that’s relatively scarce in the blood, says GentiBio CEO Adel Nada.Some biotech companies are developing Treg cell therapies from a patient’s own Tregs. GentiBio makes its Treg therapeutic candidates from an entirely different type of immune cell, and Nada says this approach...
Tags: Deals, Startups, Boston, Cancer, Trends, Investing, Biotech, Life Sciences, Autoimmune Diseases, Clinical Trials, NADA, Treg, Benaroya Research Institute, National blog main, Seattle blog main, Seattle top stories


Chernobyl fungus could shield astronauts from cosmic radiation

Radiation is one of the biggest threats to astronauts' safety during long-term missions.C. sphaerospermum is known to thrive in high-radiation environments through a process called radiosynthesis.The results of the study suggest that a thin layer of the fungus could serve as an effective shield against cosmic radiation for astronauts. When astronauts return to the moon or travel to Mars, how will they shield themselves against high levels of cosmic radiation? A recent experiment aboard the Inte...
Tags: Space, Nasa, International Space Station, Innovation, Sun, Mars, Astronauts, Biotech, Iss, Moon Mars, Fungus, Nils J H Averesch


Bio Roundup: Cerevel’s Shell, Thrive’s Rise, Drug Price Drama & More

The biotech IPO market is buzzing but Cerevel Therapeutics is showing that there’s more than one path to the public markets. This week the neuroscience drug developer reached a deal to merge with publicly traded Arya Sciences Acquisition Corp II.If you’ve never heard of Arya (NASDAQ: ARYBU), it’s a shell company that Perceptive Advisors formed specifically to serve as a vehicle to take a private company public. Cerevel is young, but it’s pretty far along. Bain Capital and Pfizer (NYSE: PFE) lau...
Tags: Deals, Sofinnova Partners, Cancer, Trends, Neuroscience, Anxiety, Schizophrenia, Autism, Alzheimer's Disease, Astrazeneca, National, GlaxoSmithKline, Novartis, Pfizer, Parkinson's Disease, Abbvie


Mammoth Biosciences’s CRISPR-based COVID-19 test receives NIH funding through RADx program

CRISPR tech startup Mammoth Biosciences is among the companies that revealed backing from the National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADx) program on Friday. Mammoth received a contract to scale up its CRISPR-based SARS-CoV-2 diagnostic test in order to help address the testing shortages across the U.S. Mammoth’s CRISPR-based approach could potentially offer a significant solution to current testing bottlenecks, because it’s a very different kind of test when c...
Tags: Health, Startups, TC, Science, Biology, Funding, Tech, United States, Fda, Biotech, Nih, Genetic Engineering, Crispr, Biotechnology, UCSF, GSK


Mammoth Biosciences’s CRISPR-based COVID-19 test receives NIH fundings through RADx program

CRISPR tech startup Mammoth Biosciences is among the companies that revealed backing from the National Institutes of Health (NIH) Rapid Accleration of Diagnostics (RADx) program on Friday. Mammoth received a contract to scale up its CRISPR-based SARS-CoV-2 diagnostic test in order to help address the testing shortages across the U.S. Mammoth’s CRISPR-based approach could potentially offer a significant solution to current testing bottlenecks, because it’s a very different kind of test when co...
Tags: Health, TC, Science, Biology, Articles, Tech, United States, Fda, Biotech, Nih, Genetic Engineering, Crispr, Biotechnology, Startup Company, UCSF, GSK


Genomics startup Helix receives $33 million in NIH funding to scale COVID-19 testing

The U.S. National Institutes of Health (NIH) is revealing the first beneficiaries of its Rapid Acceleration of Diagnostics (RADx) program, and San Mateo-based Helix is on the receiving end of $33 million in federal funding as a result. Helix is a health tech startup founded in 2015 that focuses on insights derived from personal genomics, but the company has also developed a COVID-19 test that detects the presence of SARS-CoV-2 using RT-PCR methods. The funding will be used to support Helix’s ...
Tags: Health, TC, Science, Medicine, Tech, United States, Genomics, Helix, Fda, Biotech, Nih, San Mateo, EUA, National Institute of Health, U S National Institutes of Health NIH, Coronavirus


Novartis Pays $75M to Get Hands on Sangamo’s Zinc Fingers for Drug R&D

Another biopharma has signed up to use Sangamo Therapeutics’ gene editing technology to develop therapies that can address disease by heightening or depressing a gene’s activity level.Sangamo on Thursday announced that Novartis (NYSE: NVS) had agreed to shell out $75 million up front to leverage the biotech’s genome regulation technology to treat certain neurodevelopmental conditions. Brisbane, CA-based Sangamo could earn up to $720 million in milestone payments, plus royalties on any products ...
Tags: Deals, San Francisco, Trends, Autism, Novartis, Biotech, Financing, Life Sciences, Licensing, AAV, Biogen, Gene Editing, Sangamo, Genome Editing, National blog main, National top stories


Molekule Review: An Efficient, High-End Air Purifier

If you have ever worried about the air quality in your home, you might consider an air purifier. This latest Molekule review will help you decide whether the Molekule air purifier fits your needs. The Molekule uses a two-filter system to clean the air in an area up to 600-square-feet once every hour. The pre-filter captures larger particles like dust, while the photoelectrochemical oxidation (PECO) filter breaks down viruses, bacteria, and other pollutants much smaller than those that can be ha...
Tags: Health, Wellness, Biotech, PECO, Molekule


Roche Pays $120M for Rights to UCB’s Tau-Targeting Alzheimer’s Drug

As the Alzheimer’s disease world continues to closely follow the development of therapies that break up clumps of beta amyloid on patients’ brains, Roche is placing a bet on another approach via a deal that secures rights to a clinical-stage UCB compound that targets tau, another protein associated with the neurodegenerative disorder.According to terms announced Wednesday, Roche is paying $120 million up front for global rights to the UCB drug, UCB0107. Belgium-based UCB remains responsible for...
Tags: Deals, Europe, Trends, Neuroscience, Alzheimer's Disease, Belgium, Biotech, Life Sciences, Genentech, UCB, Roche, Eisai, Biogen, Eli Lilly, Tau, National blog main


Omega Therapeutics Lands $85M to Tap Into “Control Room” of Biology

The promise of gene therapies and gene-editing drugs is a long-lasting treatment that’s potentially a cure. But making permanent genetic changes means any accompanying problems could be long-lasting as well, says Omega Therapeutics CEO Mahesh Karande.Omega is developing technology that takes a more nuanced approach to genomic medicine. Instead of fixing or replacing faulty genes, the company aims to harness the biological system that regulates them. If a gene is not properly translating DNA ins...
Tags: Deals, Startups, Trends, Investing, Mit, Novartis, Biotech, Life Sciences, Epigenetics, Genomic Medicine, Richard Young, Epizyme, National blog main, Boston blog main, Boston top stories, Whitehead Institute for Biomedical Research


XPRIZE launches $5 million rapid COVID testing competition

XPRIZE is turning its tried and tested model of offering cash prizes to spur innovation in critical areas to the challenge of COVID-19 testing. the nonprofit has created a $5 million prize pool for a Rapid COVID Testing competition, in partnership with an organization called OpenCovidScreen formed by scientists, researchers and industry leaders to drive open scientific collaboration on the topic. The competition calls for participants to develop low-cost, rapid result testing solutions that c...
Tags: Health, Startups, TC, Articles, Xprize, Biotech, Science and Technology, Coronavirus, COVID-19, COVID


Withings raises $60 million to bridge the gap between consumer tech and healthcare providers

Since being re-acquired from Nokia in 2018 by a group including its original founders and some of its original investors, health tech company Withings has been focused on evolving their offering of consumer health hardware to provide medical-grade data that can be shared with, and leveraged by healthcare professionals to deliver better, more personalized care. The company has now raised another $60 million to continue pursuing that goal, a Series B funding round co-led by Glide Healthcare, al...
Tags: Apple, Health, Fundings & Exits, Startups, TC, Science, Technology, Hardware, Withings, Nokia, Ceo, Companies, Diabetes, Hypertension, President, Healthcare Industry


Telehealth Firm AristaMD Adds $24M to Link Primary Docs With Specialists

Telemedicine isn’t just another way to connect patients with doctors. AristaMD has carved out a niche in connecting doctors with, well, other doctors.The San Diego-based telehealth company’s software links primary care physicians and medical specialists through virtual consultations, communication that is intended to reduce healthcare costs by slimming down the number of referrals made to specialty care providers. Wait times associated with specialist referrals are notoriously lengthy, during w...
Tags: Startups, Funding, Trends, Venture Capital, San Diego, Biotech, Financing, Telemedicine, Life Sciences, National blog main, San Diego blog main, San Diego top stories, AristaMD, Telehealth, Coronavirus, COVID-19


Moderna’s 30,000-participant Phase 3 COVID-19 vaccine trial kicks off in the US

The largest trial yet for a potential COVID-19 vaccine began on Monday, as drug company Moderna began providing the first of an anticipated 30,000 volunteers with shots of its candidates. This is a blind trial, wherein some participants will get the vaccine and some will get placebos. Each participant will get two doses, and researchers will study them to see which group suffers more actual infections as they proceed about their lives as they would normally. There are more than 70 anticipated tr...
Tags: Health, TC, Medicine, US, Tech, Georgia, Medical Research, United States, Vaccination, Vaccine, Biotech, Vaccines, Infection, Savannah, Savannah Georgia, National Institute of Health


Moderna’s 30,000-participant Phase 3 COVID-19 vaccine trial kicks off in the U.S.

The largest trial yet for a potential COVID-19 vaccine began on Monday, as drug company Moderna began providing the first of an anticipated 30,000 volunteers with shots of its candidates. This is a blind trial, wherein some participants will get the vaccine and some will get placebos. Each participant will get two does, and researchers will study them to see which group suffers more actual infections as they proceed about their lives as they would normally. There are more than 70 anticipated tri...
Tags: Health, Startups, TC, Medicine, Georgia, Medical Research, United States, Vaccination, Vaccine, Biotech, Vaccines, Infection, Savannah, Savannah Georgia, National Institute of Health, U S National Institutes of Health NIH


A Molekule Review That You Can Trust

The benefits of owning an air purifier are becoming more widely known, which is why these handy devices are now all the rage. Unfortunately, the market is saturated with these gadgets, so finding an adequate one can prove difficult. It’s for this reason why online testimonials are a godsend. Elaine Pofeldt, a Forbes contributor, took to the internet to give her very own Molekule review. Molekule, a manufacturing company established by Yogi Goswami, is known for its high-end air purifiers. Follo...
Tags: Health, Wellness, Biotech, Forbes, PECO, Elaine, Molekule, Yogi Goswami, Elaine Pofeldt


Roche, Jnana Enter Drug R&D Alliance Targeting Metabolism’s Gatekeepers

Scientists know that proteins called solute carrier (SLC) transporters move substances important to metabolism across cellular membranes. But can drugs effectively hit these proteins to treat disease? Roche is paying startup Jnana Therapeutics $40 million to find out.The alliance announced Tuesday focuses on the discovery and preclinical development of drugs for immunological and neurological diseases. In addition to the upfront cash payment, Roche may provide its new partner with research fund...
Tags: Startups, Boston, Trends, Harvard University, Biotech, Life Sciences, Massachusetts General Hospital, SLC, Roche, Joel Barrish, National blog main, Boston blog main, Boston top stories, Jnana, Jnana Therapeutics, Europe blog main


IBM Research develops new macromolecule that could counter antibiotic resistance

There are other persistent, grave health crises brewing besides the ongoing COVID-19 pandemic: Antibiotic resistance is one, and the troubling trend is that it’s on the rise, leading to an increase in so-called ‘superbugs’ that are difficult to treat. IBM Research, working in partnership with Singapore’s Institute of Bioengineering and Nanotechnology, has developed a synthetic macromolecule polymer that can potentially be used to significantly increase the effectiveness of existing antibiotic...
Tags: Health, TC, Science, Medicine, Singapore, Articles, Tech, Bacteria, Ibm, Nanotechnology, Biotech, Antibiotic Resistance, Veterinary Medicine, IBM Research, Institute of Bioengineering and Nanotechnology, Advanced Science the IBM


Gilead Sciences Splashes Out $300M for Tizona Stake & Option to Acquire

Gilead Sciences has made its second deal in as many months that puts the company first in line to acquire a biotech developing cancer immunotherapies.On Tuesday the Foster City, CA-based company said it would pay $300 million to South San Francisco-based Tizona Therapeutics for a 49.9 percent stake plus the option to later acquire the remainder of the company for an undisclosed fee plus potential milestone payments together totaling up to an additional $1.25 billion.Gilead Sciences (NASDAQ: GIL...
Tags: Startups, San Francisco, Trends, Venture Capital, M&a, Biotech, Financing, Life Sciences, Amgen, Gilead Sciences, Abingworth, South San Francisco, Astellas Pharma, Canaan Partners, Foster City CA, National blog main


Forge Bio’s Combo Model for Gene Therapies Attracts $40M in Funding

Forge Biologics has something rare for most early-stage biotech startups: revenue from customers. Now it has $40 million to expand its model, which places contract manufacturing alongside the development of its own gene therapies, the most advanced of which is being readied for tests in humans.From operations in Columbus, OH, Forge makes gene therapies for other companies. The company was initially conceived solely as a contract manufacturer, CEO Tim Miller (pictured above) told Xconomy. The ex...
Tags: Deals, Startups, Trends, Investing, National, Biotech, Columbus, Life Sciences, Miller, Clinical Trials, University of Pittsburgh, Tim Miller, Gene Therapy, National blog main, New York blog main, New York top stories


GSK Pays CureVac $328M in mRNA Vaccines Pact—Excluding COVID-19

GlaxoSmithKline is expanding its capabilities in messenger RNA (mRNA) research through a new alliance with CureVac spanning up to five programs targeting infectious disease pathogens.In addition to mRNA vaccines, those programs could also be antibody therapies. GSK (NYSE: GSK) is paying CureVac a total of £260 million (about $328 million) to kick off the alliance, which excludes the German company’s research on a potential COVID-19 vaccine. The British pharmaceutical giant will finance R&D of t...
Tags: Deals, Europe, Trends, GlaxoSmithKline, Infectious Disease, Vaccine, Biotech, Life Sciences, Clinical Trials, GSK, CRISPR Therapeutics, Eli Lilly, CureVac, Genmab, National blog main, Boston blog main


COVID-19 vaccine trials from the University of Oxford and Wuhan both show early positive results

There are more promising signs from ongoing efforts to develop a vaccine that’s effective in preventing COVID-19: Two early trials, one from the University of Oxford, and one from a group of researchers in Wuhan funded in part by the National Key R&D Programme of China. Both early trials showed efficacy in increasing the presence of antibody responses to SARS-CoV-2, the virus that leads to COVID-19, and also indicated that these prospective vaccines were safe to administer based on available inf...
Tags: Health, TC, Science, Medicine, China, Tech, Medical Research, Oxford, Vaccination, Vaccine, University of Oxford, Biotech, Vaccines, Pain, Wuhan, Moderna


Two Days, Six IPOs, and $1B Raised for Biotech Research & More

Summer’s arrival hasn’t slowed the momentum of the biotech IPO market. Wall Street this week welcomed six new life science industry companies, which collectively raised more than $1 billion in their stock market debuts.Relay Therapeutics (NASDAQ: RLAY) notched the biggest biotech IPO of the week, raising $400 million. Investor interest in the Cambridge, MA-based company was so strong that the company was able to boost the deal size three times. Last week, the company set a target of 14.7 millio...
Tags: Deals, Trends, Investing, Ulcerative Colitis, Medicare, Fda, National, Type 2 Diabetes, Immunotherapy, Biotech, Life Sciences, Autoimmune Diseases, Clinical Trials, Cambridge MA, National blog main, New York blog main


Bio Roundup: Moderna Publishes, Life Science Cash, AdComm Votes & More

If it seems like biotech investments have defied the financial headwinds of the pandemic, maybe it’s because they have. In the second quarter, 16 of the top 25 largest early-stage venture capital deals were investments in life science companies.The figures come from the National Venture Capital Association and financial research firm Pitchbook. This week they released their quarterly analysis of dealmaking, which shows that the tally of big biotech transactions tops the second quarter of 2019 w...
Tags: Deals, Startups, Cancer, Hiv, Trends, Investing, Merck, Infectious Diseases, Ovarian Cancer, National, Novartis, Vaccine, Immunotherapy, Biotech, Liver disease, Chemotherapy


Dewpoint, Merck Team Up to Tackle HIV Using Condensate Know-How

Dewpoint Therapeutics has signed its second biopharma partnership, teaming up with Merck to explore the potential of using its discoveries around “droplets” of biomolecules that form inside cells to create a new HIV treatment.The companies’ aim is an ambitious one: develop a drug candidate that could prove curative, rather than suppress the infection as currently available treatments do. More than 1 million people in the US alone were living with HIV in 2018, according to the latest data from t...
Tags: Deals, Startups, Boston, Hiv, US, Trends, Merck, Venture Capital, Biotech, Centers For Disease Control And Prevention, Life Sciences, Bayer, Polaris Partners, National blog main, Boston blog main, Boston top stories


Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact

A Blueprint Medicines cancer drug candidate currently under FDA review will have the marketing muscle of Roche behind it if it wins regulatory approval.The two companies are partnering on the drug, pralsetinib, a targeted cancer therapy developed for lung and thyroid cancers characterized by abnormalities in a gene called RET. According to deal terms announced Tuesday, the companies will jointly commercialize the pill in the US. Roche gains rights to sell the drug globally, except for China. Th...
Tags: Deals, China, Boston, Trends, Investing, Cambridge, Fda, Biotech, Life Sciences, Clinical Trials, Genentech, Roche, European Medicines Agency, Thermo Fisher Scientific, Eli Lilly, National blog main